ProPhase Labs, Inc.
Close on Oct 19, 2026
- Market cap
- $119.68K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2025 Ended Sep 30, 2025 | Nov 19, 2025 | Before market open | $900.00K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | $1.20M | $-0.11 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 20, 2025 | Before market open | $1.40M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $3.10M | $-0.35 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | $2.50M | $-0.33 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | $3.60M | $-0.07 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 15, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 10, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 28, 2023 | Before market open | – | – | – |
Press releases
Announcements ProPhase Labs filed with the SEC
Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury Initiative
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Financial Results for the Three Months Ended March 31, 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Financial Results for the Three Months Ended September 30, 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Pricing of Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Labs Announces Closing of Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Labs Announces Proposed Public Offering of Common Stock
Other events · EX-99.1 to Form 8-K
Labs Announces Financial Results for the Three Months Ended June 30, 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K/A
Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
the Three Months Ended September 30, 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
the Three Months Ended June 30, 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharmaceuticals Rejects ProPhase Labs Offer To Acquire Certain Assets of Navidea
Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Inc. Sets the Course for Expansion into the MENA Region with Cutting-Edge Genomic and Diagnostics Technologies
Regulation FD disclosure · EX-99.1 to Form 8-K
the Three Months Ended March 31, 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Record Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces New $6 Million Stock Repurchase Program
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic
Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Plans to Initiate Clinical Trial of Equivir (OTC)
Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand
Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy
Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Labs Acquires Rights to Novel Esophageal Cancer Test
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Record Third Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Collaboration with Dana-Farber Cancer Institute
Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Collaboration with G42 Healthcare
Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Record Second Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces New $6 Million Stock Repurchase Plan
Regulation FD disclosure · EX-99.1 to Form 8-K
Labs Announces Licensing of New Investigational Cancer Compounds
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Labs to Host Live Webcast to Discuss Business Developments on Thursday, July 21, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K